JPMorgan Chase & Co. Has $2.68 Million Stock Position in Dianthus Therapeutics, Inc. $DNTH

Key Points

• JPMorgan boosted its stake in Dianthus by 626.4% in Q3 to 68,124 shares (≈$2.68M), while other big buyers—most notably Wellington Management (2.58M shares, ≈$101.4M)—helped lift institutional ownership to 47.53%.
• Insider selling has been significant: executives sold 314,797 shares in the past 90 days worth about $25.8M (including EVP Ryan Savitz and CEO Marino Garcia), although insiders still hold 8.15% of the stock.
• Dianthus trades near its 52-week high (opened around $86) with a market cap of $3.82B and a consensus analyst target of $117.30, but the company recently missed quarterly EPS estimates (‑$1.43 vs. ‑$0.97) and remains unprofitable.

JPMorgan Chase & Co. lifted its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 626.4% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 68,124 shares of the company's stock after purchasing an additional 58,746 shares during the period. JPMorgan Chase & Co. owned 0.16% of Dianthus Therapeutics worth $2,681,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in DNTH. Wellington Management Group LLP increased its holdings in Dianthus Therapeutics by 3,366.9% during the third quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company's stock worth $101,431,000 after buying an additional 2,503,311 shares during the last quarter. Vestal Point Capital LP lifted its stake in Dianthus Therapeutics by 88.2% in the second quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company's stock valued at $59,616,000 after acquiring an additional 1,499,931 shares during the last quarter. Braidwell LP acquired a new stake in Dianthus Therapeutics in the third quarter valued at $32,859,000. Polar Capital Holdings Plc bought a new position in shares of Dianthus Therapeutics in the 3rd quarter valued at about $29,434,000. Finally, Fairmount Funds Management LLC increased its stake in shares of Dianthus Therapeutics by 22.2% during the 3rd quarter. Fairmount Funds Management LLC now owns 3,307,191 shares of the company's stock worth $130,138,000 after purchasing an additional 600,000 shares during the last quarter. Institutional investors and hedge funds own 47.53% of the company's stock.

Insider Transactions at Dianthus Therapeutics

In other news, EVP Ryan Savitz sold 114,367 shares of the company's stock in a transaction that occurred on Tuesday, March 31st. The stock was sold at an average price of $83.00, for a total value of $9,492,461.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Marino Garcia sold 122,918 shares of Dianthus Therapeutics stock in a transaction that occurred on Thursday, March 12th. The stock was sold at an average price of $81.49, for a total value of $10,016,587.82. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 314,797 shares of company stock worth $25,825,163. Insiders own 8.15% of the company's stock.

Dianthus Therapeutics Stock Performance

NASDAQ DNTH opened at $86.00 on Monday. The stock has a market cap of $3.82 billion, a PE ratio of -20.98 and a beta of 1.22. The firm has a 50-day moving average of $63.82 and a 200-day moving average of $48.10. Dianthus Therapeutics, Inc. has a 52-week low of $13.36 and a 52-week high of $88.49.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its quarterly earnings results on Monday, March 9th. The company reported ($1.43) EPS for the quarter, missing analysts' consensus estimates of ($0.97) by ($0.46). The company had revenue of $0.57 million during the quarter, compared to analyst estimates of $0.40 million. Dianthus Therapeutics had a negative net margin of 7,973.33% and a negative return on equity of 38.85%. As a group, analysts predict that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on DNTH. Robert W. Baird upped their target price on shares of Dianthus Therapeutics from $67.00 to $132.00 and gave the company an "outperform" rating in a report on Tuesday, March 10th. TD Cowen reissued a "buy" rating on shares of Dianthus Therapeutics in a research report on Monday, March 9th. Stifel Nicolaus set a $120.00 price objective on Dianthus Therapeutics in a research note on Monday, March 9th. Truist Financial raised their price objective on Dianthus Therapeutics from $63.00 to $110.00 and gave the company a "buy" rating in a research report on Monday, March 9th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Dianthus Therapeutics in a research note on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $117.30.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.

Want to see what other hedge funds are holding DNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.